Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction
Jang Hoon Lee, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim, Shung Chull Chae, Korea Acute Myocardial Infarction Registry Investigators
Korean J Intern Med. 2016;31(2):267-276. Published online 2015 Dec 23 DOI: https://doi.org/10.3904/kjim.2014.268
Citations to this article as recorded by 
Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction
Chih-Wei Chen, Chun-Wei Chang, Yi-Cheng Lin, Wan-Ting Chen, Li-Nien Chien, Chun-Yao Huang, Timir Paul
PLOS ONE.2023; 18(9): e0290251. CrossRef
Comparison of Outcomes Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Myocardial Infarction: A Meta-Analysis
Johao Escobar, Anurag Rawat, Fabricio Maradiaga, Abraham K Isaak, Sana Zainab, Mohammedsefa Arusi Dari, Martha Mekonen Gdey, Areeba Khan
Cureus.2023;[Epub] CrossRef
Targeted Delivery of Recombinant Heat Shock Protein 27 to Cardiomyocytes Promotes Recovery from Myocardial Infarction
Nahyeon Kim, Irfan Ullah, Kunho Chung, Dahye Lee, Min-Ji Cha, Hongseok Ban, Chang Seon Choi, Sunghwa Kim, Ki-Chul Hwang, Priti Kumar, Sang-Kyung Lee
Molecular Pharmaceutics.2020; 17(6): 2034. CrossRef
Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005–2014)
Gwang Sil Kim, Young-Guk Ko, Yongsung Suh, Hoyoun Won, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Korean Circulation Journal.2020; 50(11): 984. CrossRef
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction
María Cespón-Fernández, Sergio Raposeiras-Roubín, Emad Abu-Assi, Isabel Muñoz Pousa, Berenice Caneiro Queija, Rafael José Cobas Paz, Pablo Domínguez Erquicia, Luis Manuel Domínguez Rodríguez, Elena López Rodríguez, María Castiñeira Busto, Saleta Fernández
Angiology.2020; 71(10): 886. CrossRef
2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction
Hyun Kuk Kim, Youngkeun Ahn, Kiyuk Chang, Young-Hoon Jeong, Joo-Yong Hahn, Eun Ho Choo, Min Chul Kim, Hyo-Soo Kim, Weon Kim, Myeong-Chan Cho, Yangsoo Jang, Chong Jin Kim, Myung Ho Jeong, Shung Chull Chae
Korean Circulation Journal.2020; 50(10): 845. CrossRef
Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
Inho Kim, Chan Soon Park, Hae-Young Lee
Korean Circulation Journal.2019; 49(7): 615. CrossRef
Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
Dennis Ko, Paymon Azizi, Maria Koh, Alice Chong, Peter Austin, Therese Stukel, Cynthia Jackevicius
Open Heart.2019; 6(1): e001010. CrossRef
Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea
Jimin Lee, Sukhyang Lee
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2018; 38(11): 1095. CrossRef
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
The Korean Journal of Internal Medicine.2017; 32(6): 1025. CrossRef
Angiotensin converting enzyme inhibitors remain the first treatment of choice
Pyung Chun Oh, Ichiro Sakuma, Toshio Hayashi, Kwang Kon Koh
The Korean Journal of Internal Medicine.2016; 31(2): 237. CrossRef